Verdence Capital Advisors LLC Makes New Investment in Illumina, Inc. $ILMN

Verdence Capital Advisors LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,618 shares of the life sciences company's stock, valued at approximately $990,000.

Several other institutional investors have also added to or reduced their stakes in the business. Leo Wealth LLC purchased a new position in shares of Illumina in the third quarter worth about $1,981,000. Hilton Head Capital Partners LLC bought a new stake in shares of Illumina in the 3rd quarter valued at about $82,000. Leeward Financial Partners LLC purchased a new stake in Illumina during the 3rd quarter valued at about $4,410,000. Sigma Planning Corp boosted its holdings in Illumina by 91.1% during the 3rd quarter. Sigma Planning Corp now owns 6,980 shares of the life sciences company's stock valued at $1,910,000 after acquiring an additional 3,327 shares during the period. Finally, Signaturefd LLC grew its position in Illumina by 8.4% during the 3rd quarter. Signaturefd LLC now owns 5,897 shares of the life sciences company's stock worth $1,614,000 after acquiring an additional 457 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ILMN shares. JPMorgan Chase & Co. raised their price target on Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Citigroup boosted their price objective on Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a research report on Monday, August 3rd. Sanford C. Bernstein reissued a "market perform" rating and set a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. UBS Group raised Illumina from a "neutral" rating to a "buy" rating and increased their price objective for the company from $135.00 to $260.00 in a research note on Wednesday, September 9th. Finally, Wall Street Zen raised shares of Illumina from a "hold" rating to a "buy" rating in a research note on Sunday, October 11th. Ten analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $234.41.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Earnings anticipation supported the stock. Investors are looking for another revenue and adjusted-EPS beat after Illumina exceeded expectations in the second quarter and raised its full-year outlook. Analysts are likely to focus on NovaSeq X demand, clinical sequencing adoption, margins, and updated 2026 guidance. Why Illumina (ILMN) Stock Is Up Today
• Positive Sentiment: Recent operating momentum has improved investor sentiment. The company previously reported year-over-year revenue growth, stronger-than-expected results, and rising demand for its sequencing platforms and clinical applications. Several institutions also increased their Illumina holdings in recent filings, including FMR, PRIMECAP, Wellington, and Ninety One. What to expect from Illumina’s Q3 earnings
• Neutral Sentiment: The upcoming investor conference provides another potential catalyst. Illumina management is scheduled to participate in the Jefferies Global Healthcare Conference on November 17, giving investors an opportunity to hear additional commentary on demand, strategy, and the outlook. Illumina To Webcast Upcoming Investor Conference
• Negative Sentiment: Insider selling and valuation remain risks. Quiver reported 108 open-market insider sales and no purchases over the past six months, including substantial selling by Keith Meister. In addition, the reported median analyst price target of $185 is well below recent trading levels, suggesting limited near-term upside if earnings or guidance disappoint. Why Illumina (ILMN) Stock Is Up Today

Insider Activity

In related news, Director Keith Meister sold 457,858 shares of the company's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 2,061,235 shares of company stock worth $436,356,102 over the last 90 days. 2.90% of the stock is currently owned by insiders.

Illumina Trading Up 3.3%

ILMN opened at $288.79 on Thursday. The business has a 50 day simple moving average of $247.14 and a two-hundred day simple moving average of $174.99. The firm has a market capitalization of $43.61 billion, a price-to-earnings ratio of 53.88, a PEG ratio of 3.82 and a beta of 1.41. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. Illumina, Inc. has a one year low of $94.00 and a one year high of $309.35.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The business's revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $1.19 EPS. Analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Illumina Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.